Oxford biotech Exscientia enters £70M collaboration with Bill and Melinda Gates Foundation - UKTN | UK tech news
Andrew Hopkins of Exscientia: the man using AI to cure disease | Pharmaceuticals industry | The Guardian
Exscientia expands Oxford laboratories and creates 100 new jobs - European Pharmaceutical Manufacturer
Biomedical Data Quality Lead FTC Job in Exscientia Oxford, United Kingdom - Ref. 1145233
Exscientia - Exscientia Business Update for Second Quarter and First Half 2022
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease | Business Wire
Exscientia and University of Oxford launch “Xcellomics” program to expedite early-stage academic research and translate novel biology into future drug discovery — University of Oxford, Medical Sciences Division
Exscientia raises $100m to build automated drug-hunting platform | Sifted
Exscientia - Crunchbase Company Profile & Funding
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease - Hub Publishing
Exscientia | AI Drug Discovery | Pharmatech
Riassunto: Exscientia presenta i dati sulla pipeline e sulla piattaforma per la medicina di precisione all'AACR | Business Wire
Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery
Contact Us | Get In Touch | Exscientia
Exscientia | AI Drug Discovery | Pharmatech
Devin Oelofsen - Head of Hospitality - Exscientia | LinkedIn
Exscientia selects Milton Park for new laboratories - The Oxford Magazine
AI firm Exscientia takes central role in Europe's largest Covid-19 therapy development initiative - TechTribe Oxford
Exscientia: a clinical pipeline for AI-designed drug candidates – UKRI
Oxford firm to screen 15,000 drugs in search for coronavirus cure | Coronavirus | The Guardian
Exscientia appoints Oxford bioinformatics expert as first chief of biologics AI | Fierce Biotech
Exscientia extends capabilities beyond small molecules - Drug Discovery World (DDW)
